DNA酶介导的中性粒细胞胞外诱捕网溶解加速创伤患者体外凝血酶生成动力学
该研究纳入46例创伤患者与21名健康志愿者,在枸橼酸化血浆中加入或不加DNA酶(1,000 U/mL),用校准自动血栓图测凝血酶生成,并测cfDNA、CitH3、CitH4。DNA酶使创伤血浆滞后时间、达峰时间缩短,峰值升高,cfDNA与CitH3下降,H4升高(均P<0.001)。DNA酶对创伤患者的效应大于志愿者:ΔLT -0.21 vs -0.02 min(P=0.007)、ΔcfDNA -133.4 vs -84.9 ng/mL(P<0.001)、ΔCitH3 -0.65 vs -0.11 ng/mL(P=0.004)。作者认为NETs可能参与创伤患者的高凝状态。
要点
- 创伤患者血浆加DNA酶(1,000 U/mL)后滞后时间3.11 [2.67, 3.52] min降至2.93 [2.67, 3.19] min(P<0.001)。
- 达峰时间6.00 [5.30, 6.67] min降至5.48 [5.00, 6.00] min,峰值273.7 [230.7, 300.5] nM升至288.7 [257.6, 319.2] nM(均P<0.001)。
- cfDNA 576.9 [503.3, 803.1] ng/mL降至456.0 [393.5, 626.7] ng/mL,CitH3 4.54 [2.23, 10.01] ng/mL降至3.59 [1.93, 7.98] ng/mL,H4 1.30 [0.64, 6.36] ng/mL升至1.75 [0.83, 9.67] ng/mL(均P<0.001)。
- DNA酶效应创伤患者大于志愿者:ΔLT -0.21 vs -0.02 min(P=0.007)、ΔcfDNA -133.4 vs -84.9 ng/mL(P<0.001)、ΔCitH3 -0.65 vs -0.11 ng/mL(P=0.004)。
- 作者认为NETs可能参与创伤患者的高凝状态,结果为体外实验。
适用人群与场景
- 创伤患者(46例,年龄48 [31, 67]岁,67%男性)与健康志愿者(21名,年龄45 [28, 53]岁,43%男性)的枸橼酸化血浆样本,为体外实验。
处置流程与药物剂量
- 对枸橼酸化血浆样本进行DNA酶处理,浓度1,000 U/mL,比较加与不加DNA酶的凝血酶生成指标(滞后时间、峰值、达峰时间)及cfDNA、CitH3、CitH4。
研究设计与关键结果
- 研究类型为体外实验,纳入46例创伤患者和21名健康志愿者,比较血浆加与不加DNA酶(1,000 U/mL)的凝血酶生成及NET组分。
- DNA酶处理后创伤血浆滞后时间缩短(3.11 [2.67, 3.52] min vs 2.93 [2.67, 3.19] min),达峰时间缩短(6.00 [5.30, 6.67] min vs 5.48 [5.00, 6.00] min),峰值升高(273.7 [230.7, 300.5] nM vs 288.7 [257.6, 319.2] nM),均P<0.001。
- DNA酶处理后cfDNA下降(576.9 [503.3, 803.1] ng/mL vs 456.0 [393.5, 626.7] ng/mL),CitH3下降(4.54 [2.23, 10.01] ng/mL vs 3.59 [1.93, 7.98] ng/mL),H4升高(1.30 [0.64, 6.36] ng/mL vs 1.75 [0.83, 9.67] ng/mL),均P<0.001。
- DNA酶对创伤患者效应大于志愿者:ΔLT -0.21 vs -0.02 min(P=0.007),ΔcfDNA -133.4 vs -84.9 ng/mL(P<0.001),ΔCitH3 -0.65 vs -0.11 ng/mL(P=0.004)。
- 作者结论:DNA酶处理加速创伤患者样本的凝血酶生成动力学,提示NETs可能参与创伤患者的高凝状态。
证据类型、等级与局限
- 证据类型:体外实验(对创伤患者与健康志愿者血浆加或不加DNA酶处理)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该体外实验提示DNA酶(1,000 U/mL)可加速创伤患者血浆凝血酶生成并降低cfDNA、CitH3,作者认为NETs可能参与创伤患者的高凝状态;原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Neutrophil extracellular traps (NETs) trigger thrombin generation. We aimed to characterize the effects of deoxyribonuclease (DNAse) on NET components (cell-free DNA [cfDNA] and histones) and thrombin generation after trauma. Methods: Citrated plasma samples were collected from trauma patients and healthy volunteers. Thrombin generation (calibrated automated thrombogram) was measured as lag time (LT, in minutes), peak height (in nM), and time to peak thrombin generation (in minutes). Citrullinated histone 3 (CitH3) and 4 (CitH4) were measured by enzyme-linked immunosorbent assay; cfDNA by PicoGreen (all in nanograms per milliliter). Samples analyzed +/- DNAse (1,000 U/mL). Results expressed as median and quartiles [Q1, Q3], Wilcoxon testing, P < 0.05 significant. Results: We enrolled 46 patients (age, 48 [31, 67] years; 67% male) and 21 volunteers (age, 45 [28, 53] years; 43% male). Deoxyribonuclease treatment of trauma plasma led to shorter LT (3.11 [2.67, 3.52] min; 2.93 [2.67, 3.19] min), shorter time to peak thrombin generation (6.00 [5.30, 6.67] min; 5.48 [5.00, 6.00] min), greater peak height (273.7 [230.7, 300.5] nM; 288.7 [257.6, 319.2] nM), decreased cfDNA (576.9 [503.3, 803.1] ng/mL; 456.0 [393.5, 626.7] ng/mL), decreased CitH3 (4.54 [2.23, 10.01] ng/mL; 3.59 [1.93, 7.98] ng/mL), and increased H4 (1.30 [0.64, 6.36] ng/mL; 1.75 [0.83, 9.67] ng/mL), all P < 0.001. The effect of DNAse was greater on trauma patients as compared with volunteers for LT (ΔLT, -0.21 vs. -0.02 min, P = 0.007), cfDNA (ΔcfDNA -133.4 vs. -84.9 ng/mL, P < 0.001), and CitH3 (ΔCitH3, -0.65 vs. -0.11 ng/mL, P = 0.004). Conclusion: Deoxyribonuclease treatment accelerates thrombin generation kinetics in trauma patient samples as compared with healthy volunteers. These findings suggest that NETs may contribute to the hypercoagulable state observed in trauma patients.
参考来源
- Goswami J, MacArthur TA, Mahony C, et al. DNASE-MEDIATED DISSOLUTION OF NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATES IN VITRO THROMBIN GENERATION KINETICS IN TRAUMA PATIENTS. Shock. 2022. PMID: 35959777. doi:10.1097/SHK.0000000000001972
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。